Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.74), $0.01 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Morgan Stanley Resumes American Eagle Outfitters (AEO) at Equalweight
• Morgan Stanley Resumes Tapestry Inc. (TPR) at Overweight